Official announcements from Yap Inc. — partnerships, awards, funding, and more.
Press Release
Yap signs a service agreement with Italy's Icarus — adapting an AI that takes the first call at medical institutions for Japan
Yap Inc. has signed a definitive service agreement, dated August 25, 2026, with Icarus S.r.l. (brand name: Icarus Technology), an Italian company providing a voice assistant in which AI answers calls to medical institutions. Following the memorandum of understanding signed on May 28, 2026, Yap now begins the research needed to adapt the service to Japanese healthcare settings. The name for the Japanese market is "Kyoko AI." No launch date in Japan has been decided at this time.
Yap Signs Memorandum of Understanding with Italy's Icarus S.r.l.
Yap Inc. has signed a Memorandum of Understanding (MoU) on a business partnership with Icarus S.r.l. (product brand: Icarus Technology), a company based in Sardinia, Italy. The MoU follows business development meetings in Tokyo, with the support of the Italian Trade Agency (ITA) and Regione Autonoma della Sardegna, and through SusHi Tech Tokyo, hosted by the Tokyo Metropolitan Government, and the venue of Tokyo Innovation Base. Icarus provides a multilingual AI voice assistant that automates patient phone reception for clinics; together the two companies aim to combine this with Yap's healthcare business and AI capabilities to expand in the Japanese market.
Yap Signs Partnership Agreement with Indonesian Digital Biobank Asa Ren
Yap Inc. has signed a business partnership agreement with Asa Ren, an Indonesian digital biobank company. Asa Ren operates Southeast Asia's first AI-powered digital biobank, integrating clinical and genomic data across diverse ethnic groups to advance personalized medicine and drug discovery. The two companies aim to expand awareness and adoption of Asa Ren's digital biobank.
Yap Signs Import Agreement with Bangladesh's UniMed UniHealth — First Bangladeshi Pharma to Enter Japan
Yap Inc. has signed an import agreement with UniMed UniHealth Pharmaceuticals Limited of Bangladesh. The agreement marks the first entry of a Bangladeshi pharmaceutical company into the Japanese market, beginning with Novotin, a biotin-based nutritional supplement.
Healthcare commentary shared by CEO Masaya Yamamoto on NewsPicks.
Platform
Filter by Tag
NewsPicksSeptember 4, 2026
熱中症対策の本質 ― 気温より社会制度の穴を埋めよ
The Japan Meteorological Association forecasts that broad regions—including Kanto, Tokai, Kinki, Kyushu, and Okinawa—will face 'strict alert' or even 'danger' level heat through the first half of September, and the pattern of prolonged late-summer heat is not unique to this year. Yet the core issue, in my view, lies less in temperature itself than in gaps within our social systems. As European heat waves have repeatedly demonstrated, the isolation of elderly people and the absence of welfare-check infrastructure dramatically elevate mortality risk. In Japan, a growing number of elderly people living alone have air conditioners but cannot use them effectively due to anxiety over electricity bills or difficulty operating the units—meaning installation rates alone paint a misleading picture. As this article rightly points out, nighttime heatstroke is closely tied to housing conditions and air-conditioner use, so addressing the economic and cognitive barriers that prevent that use is precisely where government and local communities must focus. Even as weather forecasting grows more sophisticated, the monitoring networks needed to translate that information into behavioral change have not kept pace. We need to deliberately design solutions that distinguish between what technology can handle and what requires human networks.
Heatstroke PreventionElderly Care & MonitoringSocial Infrastructure
The prospective observational findings showing a significant reduction in dementia risk associated with resistance training and gateball are intriguing, yet residual confounding—such as frequency of social participation and baseline physical and cognitive function at the time individuals took up each activity—cannot be ruled out. Those who manage to make these activities a habit may already have higher physical function and health awareness, making it difficult to fully dismiss selection bias; reading the results as straightforward evidence that 'these specific sports work' should be avoided. That said, what concerns me is how public health authorities, who currently find it difficult to drill down to the level of specific activity types in their exercise recommendations, should interpret this kind of sport-specific risk data. The differences in risk by activity type revealed in this study could serve as one input for refining future guidelines, but a single observational study is not yet sufficient to drive policy design. I would like to see reproducibility confirmed across multiple prospective and intervention studies before these findings are reflected in the way specific activities are prescribed.
Dementia PreventionExercise & Physical ActivityPublic Health Policy
The 10-million-yen move-in fee now common at Tokyo nursing homes signals that senior housing has entered the realm of asset-allocation decisions—but the explosive growth of home-based tech care reflects something deeper: a cultural shift in where people want to age, not merely a difference in price point. What deserves close attention is the uneven distribution of that technology's benefits. Sensing devices, remote monitoring, and AI-driven condition alerts are genuinely advancing, yet they remain theoretical without the right family support, living environment, and communications infrastructure in place—raising serious questions about how far these tools can reach rural seniors living alone. From a care-continuity standpoint, for home tech care to function as a genuine 'place to live and die,' it must be architecturally integrated with visiting physicians and home-visit nursing teams. The real inflection point for adoption will not be product sophistication, but whether the solution can be embedded into local care teams on the ground.
Home Care TechnologyCare Access InequalityMedical-Care Integration
Even when dressed up as 'sleep beauty,' what is actually being prescribed are psychotropic drugs—and that structural mismatch deserves clear recognition. Prescribing sleep medications and anxiolytics in private-pay clinics falls within a physician's discretion and is not illegal, but the real issues are the appropriateness of the indication and the quality of informed consent. A serious concern is whether patients who sought treatment for cosmetic reasons genuinely understand the risk of dependence before accepting a prescription. The dependence risk associated with benzodiazepines and non-benzodiazepine agents is well documented even with short-term use, and managing withdrawal requires specialist follow-up. A scenario in which a patient 'started for beauty purposes and couldn't stop' not only harms the individual but also erodes trust in medicine more broadly. While the private-pay model itself need not be rejected outright, we must ask whether adequate medical evaluation is in place at both the entry and exit points of prescribing—and alongside regulatory debate, scrutiny of the clinical ethics standards held by prescribing physicians is equally indispensable.
The WHO's announcement of 70,000 doses of Ervebo for the Congo is a timely reminder of what might be called 'vaccine geopolitics' in infectious disease response. Ervebo, developed by Merck and validated during the 2019 Congo outbreak, is effective—but the greater challenge lies not in the product itself, rather in the supply chain: who delivers it, when, and where. Worth scrutinizing is the basis for that 70,000-dose figure. Given Ebola's transmission dynamics, ring vaccination guided by contact tracing is the standard strategy, not broad population-level immunization; whether the dosage estimate is epidemiologically sound hinges directly on the quality of local surveillance systems. From a Japanese perspective, international contributions to infectious disease response rarely surface in domestic discourse. Yet pathogens respect no borders, and the combination of vaccine supply capacity and diplomatic leverage is, in essence, a matter of national security. The time has come for both the public and private sectors in Japan to seriously explore how Japanese companies and technologies can play a meaningful role in the supply chains that underpin initiatives like this one.
Infectious Disease ResponseVaccine DiplomacyGlobal Health
The article suggests that brain energy production drops to around 60% of its peak by age 80, and while the age-related decline in metabolic efficiency is a reasonable observation, the causal chain linking a reduction in the TCA cycle directly to the accumulation of amyloid-β or Lewy bodies is not yet firmly established by strong evidence—and should be read with caution. The free portion of the article also fails to spell out the substance or scientific basis of the five principles it touts, meaning the practical value depends heavily on what 'appropriate care' actually entails. My top recommendation for Japanese business professionals is straightforward: correct chronic sleep debt. No special intervention is needed—simply move tonight's bedtime 30 minutes earlier. That, in my view, is the most realistic and cost-effective first step available.